Protagenic Therapeutics granted new patent in Japan for modified stilbenoid

Protagenic Therapeutics (PTIX) announces that on July 18, 2025, the Japanese Patent Office granted Patent JP 7714571B, a patent which runs until March 31, 2041. This patent underpins one of the Company’s key pipeline assets, a modified stilbenoid, and importantly provides the Company with exclusivity to particular compounds per se, formulations containing a number of drug candidates, and their medical use, which is to treat epilepsy and seizures. Colin Stott, Chief Operating Officer of Protagenic Therapeutics, Inc. said: “We are delighted to announce the grant of this important patent for the Company in Japan. Such a grant builds on the previous grant of the same patent in the UK, and demonstrates the ability of the Company to continue its innovative approach and to add value and important protection to its development pipeline for shareholders. We anticipate applying to expand the grant of this patent in other territories in the future.”